Chemoprevention Trial for Men at High Risk for Prostate Cancer
Name of the Trial
Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients
with High-Grade Prostatic Intraepithelial Neoplasia (SWOG-S9917). See the protocol summary 3.
Principal Investigators
Dr. Jim Marshall, Southwest Oncology Group; Dr. David Jarrard, Eastern Cooperative
Oncology Group; and Dr. William Robert Lee, Cancer and Leukemia Group B.
.jpg) |
Dr. Jim Marshall
Principal Investigator |
Why This Trial Is Important
Prostate cancer is an important source of morbidity and mortality among men in the industrialized world.
High-grade prostatic intraepithelial neoplasia (HGPIN), a condition characterized by
abnormal and uncontrolled growth of the ductal cells of the prostate, may be a precursor to
prostate cancer.
Intake of the dietary supplement selenium is believed to protect against prostate cancer.
Researchers are interested in determining whether a daily dose of selenium might prevent
prostate cancer from developing among men with HGPIN.
“HGPIN is very likely a premalignant lesion for prostate cancer, so it is important to find a chemopreventive agent that will be effective for this high-risk
group,” said Dr. Marshall. “Selenium supplementation shows promise, so we need
to know if it might prevent HGPIN from developing into prostate cancer.”
Contact Information
This trial is no longer accepting new patients. To locate other clinical trials
for prostate cancer, search the NCI's database of clinical
trials 1 or call the NCI’s Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237). The call is toll free and completely confidential.
Published Results
Marshall JR, Sakr W, Wood D, et al.: Design and progress of a trial of selenium to
prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
Cancer Epidemiol Biomarkers Prev 15 (8): 1479-84, 2006.[PUBMED Abstract]
Sakr WA, Faulkner JR, Wood D: Low rate of confirming prostate cancer on repeat biopsies
following diagnosis of high grade prostatic intraepithelial neoplasia: preliminary analysis
of Southwest Oncology Group study s9917. [Abstract] Proceedings of the American Association
for Cancer Research 45: A-1333, 305, 2004. |
